Počki (Apr 2013)

Active Follow-up in Patients with Localized Prostate Cancer: Evaluation of Long-term Results

  • S.O. Vozianov,
  • V.M. Grygorenko,
  • R.O. Danylets,
  • A.V. Bardin,
  • L.V. Pereta

DOI
https://doi.org/10.22141/2307-1257.0.2.04.2013.85343
Journal volume & issue
Vol. 2, no. 2.04
pp. 7 – 10

Abstract

Read online

Among the clinical recommendations one of the standard approaches in the treatment of prostate cancer is active follow-up. For 13 years, under the supervision there were 85.7 % of patients. Overall 3-, 5- and 7-year survival rate was 93.2 ± 4.6 %, 70.8 ± 9.1 % and 50.9 ± 10.2 %, respectively. 14.3% of patients died due to comorbidities. The average time of survival was 136 months. These data substantiate the feasibility of active follow-up from medical, social and economic point of view. Optimal results can be achieved with the right selection, the criteria of which are: the level of prostate-specific antigen ≤ 10 ng/ml, Gleason grading score ≤ 6, age, multiple organ pathology.

Keywords